Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

England’s New Innovative Medicines Fund ‘Must Be Future Proof’

A public engagement exercise on the new plan in due in Q1 2021

Executive Summary

When establishing the new fund, lessons should be learned from the Cancer Dugs Fund so other disease areas are not neglected, say experts.

You may also be interested in...



UK Urged To Fund Rare Disease Treatments Immediately

Genetic Alliance UK says companies should be clear about how they price rare disease treatments and that the government should explain how it assesses affordability.

UK Conservatives Promise ‘Innovative Medicines Fund’ If Re-Elected

More money to pay for innovative new medicines, more cash and support for the life sciences sector, and Brexit by 31 January 2020 are among promises made in the Conservative Party’s election platform. 

At Last: Vertex Strikes CF Deal In England

After years of stalemate, NHS England and Vertex have finally agreed a deal that will see cystic fibrosis patients access Orkambi and Symkevi as well as allow more patients to benefit from Kalydeco.

Topics

UsernamePublicRestriction

Register

PS143685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel